Abstract
Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have